Want to join the conversation?
$MRK said that the US Food and Drug Administration has granted Breakthrough Therapy Designation to KEYTRUDA (pembrolizumab), its anti-PD-1 therapy, for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma. The company stated that this is the fourth Breakthrough Therapy Designation granted for KEYTRUDA.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.